Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Beyond Air ( (XAIR) ) just unveiled an update.
On June 16, 2025, Beyond Air appointed Robert Goodman to its Board of Directors, bringing his extensive experience in healthcare leadership to the company. Additionally, Beyond Air announced the submission of a premarket approval supplement to the FDA for its second-generation LungFit PH device, which could significantly enhance its market potential. The company reported a 220% increase in annual revenue for the fiscal year ending March 31, 2025, driven by the demand for LungFit PH and international expansion. Despite a net loss, Beyond Air’s strategic moves, including new distribution partnerships and regulatory approvals, position it for a pivotal year ahead.
The most recent analyst rating on (XAIR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Spark’s Take on XAIR Stock
According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral.
Beyond Air’s overall score reflects significant financial challenges, with persistent losses and cash flow issues undermining its financial health. Despite recent revenue growth and strategic international expansion, the company’s valuation remains weak due to ongoing losses and the absence of dividends. Technical indicators suggest bearish sentiment, though corporate events and earnings call highlights show potential for future improvements if strategic initiatives are successfully implemented.
To see Spark’s full report on XAIR stock, click here.
More about Beyond Air
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company that focuses on harnessing the power of nitric oxide to improve patient outcomes. The company is actively involved in the development and commercialization of its LungFit PH system, a cylinder-free nitric oxide delivery system, and is expanding its market presence internationally.
Average Trading Volume: 2,541,223
Technical Sentiment Signal: Sell
Current Market Cap: $15.51M
For an in-depth examination of XAIR stock, go to TipRanks’ Overview page.